Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.68
−$0.08 · -4.55%
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Latest quote
$1.68
−$0.08 · -4.55%
After-hours
$1.6998
+$0.0198 · +1.18%
Oct 9, 6:41 PM ET
Regular session · ET · Market data may be delayed.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Day range
Current $1.68
52-week range
Current $1.68
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
55
Mixed
Risk
53
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Day range
Current $1.68
52-week range
Current $1.68
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 49.8M USD | 31.08M USD | 1.2M USD | 139K USD | 298K USD |
| Cost of goods sold | 274K USD | 616K USD | 58.97M USD | 52.52M USD | 55.05M USD |
| Gross profit | 49.53M USD | 30.47M USD | −57.77M USD | −52.38M USD | −54.75M USD |
| Research and development | 61.12M USD | 84.48M USD | 58.89M USD | 52.82M USD | 55.05M USD |
| Selling, general, and administrative | 37.32M USD | 131.9M USD | — | — | — |
| Operating expenses | 98.44M USD | 227.58M USD | 113.98M USD | 48.38M USD | 32.34M USD |
| Interest income | 6.91M USD | 12.29M USD | 7.73M USD | 1.6M USD | 134K USD |
| Interest expense | 8.34M USD | 15.58M USD | 13.1M USD | 2.78M USD | 802K USD |
| Depreciation and amortization | 621K USD | 534K USD | 554K USD | 427K USD | 292K USD |
| Operating income | −48.91M USD | −197.12M USD | −171.75M USD | −100.76M USD | −87.09M USD |
| Net income | −50.34M USD | −200.4M USD | −177.12M USD | −101.94M USD | −87.76M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
257.14% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 21, 2015 | 1:7 | — | — |
Effective May 21, 2015
1:7
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI15.94M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM10.58M0.01%77.7B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF5.91M0.01%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO3.71M0.03%14.04B USD0.24%$356.78+0.94%
State Street SPDR S&P Pharmaceuticals ETFXPH3.55M0.78%453.39M USD0.35%$64.65+1.60%
Vanguard Russell 2000 ETFVTWO3.22M0.02%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1.97M0.01%21.73B USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT1.45M0.01%22B USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
